Myriad gene patent case sparks concern among non-medical biotech companies
Twenty-three companies have sent a joint letter to the attorney general and solicitor general of the United States to ask that their concerns be considered as the government develops its position on the Myriad gene patent case
The Myriad case was remanded to the Federal Circuit in March following the Supreme Court’s decision in Mayo v Prometheus. Under the Prometheus decision, the Federal Circuit must reevaluate its July 2011 ruling in favour of Myriad Genetics.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.